{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T06:12:06Z","timestamp":1760076726495,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.gcb.2010.08.008","type":"journal-article","created":{"date-parts":[[2010,12,24]],"date-time":"2010-12-24T04:33:54Z","timestamp":1293165234000},"page":"34-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Lymphocytosis as a predictor of poor response to treatment of hepatitis C"],"prefix":"10.1016","volume":"35","author":[{"given":"A.","family":"Martinez-Camacho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.I.","family":"Khaoustov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Adam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.E.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Tavakoli-Tabasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Yoffe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gcb.2010.08.008_bib0005","doi-asserted-by":"crossref","first-page":"47","DOI":"10.7150\/ijms.3.47","article-title":"The natural history of hepatitis C virus infection","volume":"3","author":"Chen","year":"2006","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.gcb.2010.08.008_bib0010","unstructured":"World Health Organization. Hepatitis C: fact sheet no. 164. http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en."},{"key":"10.1016\/j.gcb.2010.08.008_bib0015","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJM199908193410802","article-title":"The prevalence of hepatitis C virus infection in the United States, 1988 through 1994","volume":"341","author":"Alter","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gcb.2010.08.008_bib0020","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","article-title":"The prevalence of hepatitis C virus infection in the United States, 1999 through 2002","volume":"144","author":"Armstrong","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.gcb.2010.08.008_bib0025","unstructured":"US Department of Health and Human Services. 2005 Annual report of the U. S. OPTN and SRTR: Transplant Data 1995\u20132004 Rockville, MD: Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation."},{"key":"10.1016\/j.gcb.2010.08.008_bib0030","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMct061675","article-title":"Peginterferon and ribavirin for chronic hepatitis C","volume":"355","author":"Hoofnagle","year":"2006","journal-title":"N Engl J Med"},{"issue":"40","key":"10.1016\/j.gcb.2010.08.008_bib0035","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose","volume":"1","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.gcb.2010.08.008_bib0040","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gcb.2010.08.008_bib0045","doi-asserted-by":"crossref","first-page":"112S","DOI":"10.1002\/hep.510260720","article-title":"Side effects of alpha interferon in chronic hepatitis C","volume":"26","author":"Dusheiko","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.gcb.2010.08.008_bib0050","doi-asserted-by":"crossref","first-page":"237S","DOI":"10.1002\/hep.1840360730","article-title":"Side effects of therapy of hepatitis C and their management","volume":"36","author":"Fried","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.gcb.2010.08.008_bib0055","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jhep.2008.07.013","article-title":"Treatment predictors of a sustained virologic response in hepatitis B and C","volume":"49","author":"Kau","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.gcb.2010.08.008_bib0060","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1053\/j.gastro.2006.06.008","article-title":"Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1","volume":"131","author":"Conjeevaram","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gcb.2010.08.008_bib0065","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jhep.2003.11.004","article-title":"The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients","volume":"40","author":"Patton","year":"2004","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.gcb.2010.08.008_bib0070","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jhep.2008.12.017","article-title":"Insulin resistance predicts response to peginterferon-alpha\/ribavirin combination therapy in chronic hepatitis C patients","volume":"50","author":"Dai","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.gcb.2010.08.008_bib0075","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1111\/j.1440-1746.2006.04759.x","article-title":"Hepatic iron accumulation is associated with disease progression and resistance to interferon\/ribavirin combination therapy in chronic hepatitis C","volume":"22","author":"Fujita","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.gcb.2010.08.008_bib0080","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1056\/NEJMoa032502","article-title":"Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-hispanic whites","volume":"350","author":"Muir","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gcb.2010.08.008_bib0085","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: an update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.gcb.2010.08.008_bib0090","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1053\/jhep.2003.50364","article-title":"Early virologic response to treatment with Peginterferon alpha-2b plus ribavirin in patients with chronic hepatitis C","volume":"38","author":"Davis","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.gcb.2010.08.008_bib0095","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/hep.22061","article-title":"Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial","volume":"47","author":"Mangia","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.gcb.2010.08.008_bib0100","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1002\/hep.22543","article-title":"Pretreatment prediction of virologic response peginterferon plus ribavirin therapy in chronic hepatitis C patient using viral and host factors","volume":"48","author":"Shirakawa","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.gcb.2010.08.008_bib0105","doi-asserted-by":"crossref","first-page":"486","DOI":"10.7326\/0003-4819-146-7-200704030-00004","article-title":"Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences","volume":"146","author":"Hsieh","year":"2007","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.gcb.2010.08.008_bib0110","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1046\/j.1365-2893.2001.00312.x","article-title":"Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy","volume":"8","author":"McHutchison","year":"2001","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.gcb.2010.08.008_bib0115","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1006\/clim.1998.4663","article-title":"Costimulatory pathways mediate monocyte-dependent lymphocyte apoptosis in HIV","volume":"90","author":"Lewis","year":"1999","journal-title":"Clin Immunol"},{"key":"10.1016\/j.gcb.2010.08.008_bib0120","doi-asserted-by":"crossref","first-page":"17420","DOI":"10.1016\/S0021-9258(18)38177-8","article-title":"Binding of annexin\u00a0V\/placental anticoagulant protein I to platelets. Evidence for phosphatidylserine exposure in the procoagulant response of activated platelets","volume":"65","author":"Thiagarajan","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1016\/j.gcb.2010.08.008_bib0125","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1053\/jhep.2003.50103","article-title":"Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response","volume":"37","author":"Sugimoto","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.gcb.2010.08.008_bib0130","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/nri1349","article-title":"Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity","volume":"4","author":"Chen","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.gcb.2010.08.008_bib0135","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.4049\/jimmunol.180.6.3637","article-title":"Cutting Edge: Programmed death-1 expression is increased on immunocytes in chronic hepatitis C virus and predicts failure of response to antiviral therapy: race-dependent differences","volume":"180","author":"Golden-Mason","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.gcb.2010.08.008_bib0140","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1365-2893.2006.00804.x","article-title":"Clinical responders to antiviral therapy of chronic HCV infection show elevated antiviral CD4+ and CD8+ T-cell responses","volume":"14","author":"Pillai","year":"2007","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.gcb.2010.08.008_bib0145","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1086\/513278","article-title":"CD4+ T cell responses in patients with chronic hepatitis C undergoing peginterferon\/ribavirin therapy correlates with faster, but not sustained, viral clearance","volume":"195","author":"Aberle","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.gcb.2010.08.008_bib0150","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.virol.2005.11.017","article-title":"Apoptosis of activated CD4+ and CD8+ T cells is enhanced by co-culture with hepatocytes expressing hepatitis C virus (HCV) structural proteins through FasL induction","volume":"346","author":"Iken","year":"2006","journal-title":"Virology"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399832010003064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399832010003064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T05:36:06Z","timestamp":1760074566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0399832010003064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0399832010003064"],"URL":"https:\/\/doi.org\/10.1016\/j.gcb.2010.08.008","relation":{},"ISSN":["2210-7401"],"issn-type":[{"type":"print","value":"2210-7401"}],"subject":[],"published":{"date-parts":[[2011,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lymphocytosis as a predictor of poor response to treatment of hepatitis C","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gcb.2010.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}